



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/955,006	09/17/2001	Robert J. Schneider	5914-084-999	7849

20583 7590 06/18/2002

PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711

EXAMINER

LI, BAO Q

ART UNIT PAPER NUMBER

1648

DATE MAILED: 06/18/2002

5

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/955,006	Applicant(s) SCHNEIDER ET AL.	
	Examiner Bao Qun Li	Art Unit 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03/14/2002.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-21 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: |

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-12, drawn to a method for treating hepatitis B (HBV) infection through the mechanism of blocking the translation of Pyk2 kinase, classified in class 514, subclass 44.

Upon election of Group I, Applicant is additionally required to elect one kind of compounds from 1), antisense and 2) ribozyme 3), pyrolozopyrimidine 4) benzylidemalonitrile and 5). A dominant-negative mutant of Pyk2 kinase to be examined on the merits. This requirement is not to be construed as a requirement for an election of species, since each of the nucleotide molecule recited in alternative form is not a member of a single genus of invention, but constitute an independent and patentably distinct invention.

- II. Claims 1 and 13-14, drawn to a method for treating the HBV infection through the target protein of HBx, classified in class 435, subclass 339.
- III. Claims 15-18, drawn to a method for treating HBV infection through the mechanism of modulating the cytosolic calcium release, classified in class 424, subclass 9.1.
- IV. Claim 19, drawn to a pharmaceutical formulation for treatment of HBV infection comprising a compound that inhibits the activation of a Pyk2 kinase, classified in class 536, subclass 24.5.
- V. Claim 20, drawn to a pharmaceutical formulation for treatment of HBV infection comprising a compound that inhibits HBx, classified in class 514, subclass 49.
- VI. Claim 21, drawn to a pharmaceutical formulation for treatment of HBV infection comprising a compound that sustain the HBV life cycle, classified in class 514, subclass 11.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different

Art Unit: 1648

inventions of group I-IV are drawn to different methods for treating HBV infection. They are not disclosed as capable of use together and each of them has a different modes of operation, different functions or different effects. For example, the method of the group I is directed to use a compound for inhibiting the Pyk2 kinase activity, whereas the method of Group III use a monocyclic compound, cyclosporine, for interfering the calcium metabolic pathway of the cell.

Inventions IV and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed could be used in material different process of using the product, such as the cyclosporine can be used for inhibiting the immune response after autograft, whereas, the process for using the product as claimed can be practiced with another material different product, such as Interferon.

Because these inventions are distinct for the reasons given above and the search required for one group does not necessarily need to search another group, e.g. Group I is not required for Group VII, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 703-305-1695. The examiner can normally be reached on 8:00 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4027. The fax phone numbers for the

Application/Control Number: 09/955,006
Art Unit: 1648



Page 4

organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Bao Qun Li

June 14, 2002

A handwritten signature in black ink, appearing to read "Bao Qun Li", with a long vertical stroke extending downwards from the end of the signature.A handwritten signature in black ink, appearing to read "Ali R. Salimi", positioned above a rectangular stamp. The stamp contains the text "ALI R. SALIMI" and "PRIMARY EXAMINER" in a bold, sans-serif font, oriented diagonally.